TECXTectonic Therapeutic, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$83M
- 47% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$212M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$119M | −$105M | −$45M | −$58M | −$84M | 45% |
| Net income | −$119M | −$106M | −$42.8B | −$58.0B | −$74.2B | 28% |
| Operating cash flow | −$98M | −$97M | −$41M | −$59M | −$60M | 1.7% |
| Capex | $2M | $267K | $279K | $156K | $208K | 33% |
| Stock-based comp | $19M | $12M | $1M | $3M | $10M | 201% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $14K · 2
- Net
- −$14K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 244 | — |
| FY2024 | — | — | 540 | — |
| FY2023 | — | — | 191 | — |